Stock within investor Spotlight: Nektar Therapeutics (NKTR)

Barsaba Taglieri
Luglio 26, 2017

The institutional investor owned 63,200 shares of the biopharmaceutical company's stock after buying an additional 500 shares during the period.

A number of other brokerages have also recently weighed in on NKTR. Prudential Financial Inc. raised its stake in shares of Nektar Therapeutics by 1.1% in the first quarter. Insiders have sold 159,803 shares of company stock valued at $3,328,247 over the last 90 days. Aperio Group LLC increased its position in Nektar Therapeutics by 11.0% in the second quarter. Prudential Financial Inc. now owns 262,243 shares of the biopharmaceutical company's stock worth $6,155,000 after buying an additional 2,890 shares during the last quarter. NY increased its position in shares of Nektar Therapeutics by 9.7% in the fourth quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company's stock valued at $184,000 after buying an additional 784 shares during the last quarter. Norges Bank purchased a new position in shares of Nektar Therapeutics during the fourth quarter worth approximately $31,574,000. Finally, Elkfork Partners LLC boosted its stake in Nektar Therapeutics by 11.1% in the first quarter.

NKTR-358, discovered and initially developed by Nektar, has the potential to modulate immune system responses to re-establish an immune balance in patients with autoimmune disorders. The company has a 50-day moving average of $19.35 and a 200 day moving average of $16.66. Nektar has the option to participate in late-stage development on an indication-by-indication basis, could receive royalties that increase depending on its phase 3 investment and product sales and will have the option to co-promote the drug in the US, the company said.

Nektar Therapeutics (NASDAQ:NKTR), stock is trading $24.88 above the 52-week high and has displayed a high EPS growth of 1.50% in last 5 years.

Media stories about Nektar Therapeutics (NASDAQ:NKTR) have been trending positive this week, Accern Sentiment reports. The company's reported earnings per share guidance in 2017 is expected to be reduced by the amount of the charge. The firm had revenue of $24.73 million for the quarter, compared to the consensus estimate of $29.43 million. The business's revenue for the quarter was down 58.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) EPS.

Nektar Therapeutics (NASDAQ:NKTR), maintained return on investment for the last twelve months at -45.19, higher than what Reuters data shows regarding industry's average. The third largest holder is Blackrock Inc., which now holds $445.59 million worth of this stock and that ownership represents almost 12.55% of its market capitalization. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & global trademark and copyright legislation. Jefferies Group LLC decreased their price objective on shares of Nektar Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a report on Wednesday, May 10th. Finally, Aegis increased their price objective on shares of Nektar Therapeutics from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Monday, March 20th. William Blair reaffirmed an "outperform" rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. ValuEngine upgraded Nektar Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, June 2nd. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Nektar Therapeutics now has an average rating of "Buy" and a consensus target price of $26.29.

In related news, SVP Stephen K. Doberstein sold 1,701 shares of the company's stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $19.55, for a total transaction of $163,985.40. Following the completion of the transaction, the senior vice president now directly owns 98,492 shares in the company, valued at approximately $2,078,181.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lutz Lingnau sold 30,000 shares of the business's stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $21.10, for a total value of $1,158,812.00. The disclosure for this sale can be found here. Lilly and Nektar will co-develop NKTR-358 with Nektar responsible for completing Phase 1 clinical development.

Altre relazioni OverNewsmagazine

Discuti questo articolo